Jeffrey A. Silverman

5.0k total citations · 1 hit paper
93 papers, 3.8k citations indexed

About

Jeffrey A. Silverman is a scholar working on Oncology, Molecular Biology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Jeffrey A. Silverman has authored 93 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 38 papers in Molecular Biology and 21 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Jeffrey A. Silverman's work include Drug Transport and Resistance Mechanisms (31 papers), Acute Lymphoblastic Leukemia research (15 papers) and Pharmacological Effects and Toxicity Studies (12 papers). Jeffrey A. Silverman is often cited by papers focused on Drug Transport and Resistance Mechanisms (31 papers), Acute Lymphoblastic Leukemia research (15 papers) and Pharmacological Effects and Toxicity Studies (12 papers). Jeffrey A. Silverman collaborates with scholars based in United States, Canada and Germany. Jeffrey A. Silverman's co-authors include Jay Dintaman, Steven R. Deitcher, Vincent J. Wacher, Leslie Z. Benet, Snorri S. Thorgeirsson, Yuanchao Zhang, Timothy W. Gant, Dieter Schrenk, Pamela A. Marino and Takashi Izumi and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jeffrey A. Silverman

90 papers receiving 3.7k citations

Hit Papers

Marqibo® (vincristine sulfate liposome injection) improve... 2012 2026 2016 2021 2012 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine
    2012 341 citations Jeffrey A. Silverman, Steven R. Deitcher Cancer Chemotherapy and Pharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeffrey A. Silverman United States 35 2.0k 1.1k 856 619 450 93 3.8k
Micheline Piquette‐Miller Canada 46 2.7k 1.4× 1.0k 0.9× 1.1k 1.3× 1.0k 1.6× 560 1.2× 128 5.3k
Mikihisa Takano Japan 37 2.1k 1.1× 1.6k 1.4× 1.1k 1.3× 688 1.1× 155 0.3× 185 4.9k
Teruo Murakami Japan 30 1.2k 0.6× 817 0.7× 714 0.8× 588 0.9× 269 0.6× 135 3.2k
Jae‐Yong Chung South Korea 32 805 0.4× 885 0.8× 533 0.6× 460 0.7× 569 1.3× 172 3.7k
Johan W. Smit Netherlands 28 2.4k 1.2× 912 0.8× 1.2k 1.5× 651 1.1× 117 0.3× 45 3.8k
Alan V. Boddy United Kingdom 41 2.2k 1.1× 2.4k 2.1× 645 0.8× 620 1.0× 520 1.2× 188 5.9k
Katsuhiko Okumura Japan 39 2.3k 1.2× 1.4k 1.3× 1.3k 1.5× 874 1.4× 126 0.3× 179 5.2k
Ashim K. Mitra United States 41 1.2k 0.6× 1.5k 1.3× 573 0.7× 379 0.6× 251 0.6× 144 4.6k
Masato Yasuhara Japan 28 898 0.5× 1.0k 0.9× 620 0.7× 303 0.5× 163 0.4× 126 3.5k
Sharon Marsh United States 43 3.0k 1.5× 2.9k 2.6× 589 0.7× 1.1k 1.8× 353 0.8× 109 6.7k

Countries citing papers authored by Jeffrey A. Silverman

Since Specialization
Citations

This map shows the geographic impact of Jeffrey A. Silverman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey A. Silverman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey A. Silverman more than expected).

Fields of papers citing papers by Jeffrey A. Silverman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey A. Silverman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey A. Silverman. The network helps show where Jeffrey A. Silverman may publish in the future.

Co-authorship network of co-authors of Jeffrey A. Silverman

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey A. Silverman. A scholar is included among the top collaborators of Jeffrey A. Silverman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey A. Silverman. Jeffrey A. Silverman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dufton, Christopher, Marc Evanchik, David G. Daniel, et al.. (2025). EDG-7500, A First-in-Class Cardiac Sarcomere Modulator, Demonstrates Favorable Tolerability, Safety, And Pharmacokinetics In Healthy Adults. Journal of Cardiac Failure. 31(1). 345–345. 3 indexed citations
2.
Lin, Tong, et al.. (2023). Population pharmacokinetics of intramuscular recombinant Erwinia chrysanthemi asparaginase (JZP458) in patients with acute lymphoblastic leukemia. Clinical and Translational Science. 16(5). 898–909. 2 indexed citations
3.
4.
Mokhtari, Sepideh, Jeffrey A. Silverman, Kayla Reid, et al.. (2021). Transverse myelitis after anti‐CD19 directed CAR T cell therapy for relapsed large B cell lymphoma. SHILAP Revista de lepidopterología. 3(1). 223–227. 10 indexed citations
5.
Shah, Manish A., Alexander Starodub, Sunil Sharma, et al.. (2018). Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. Clinical Cancer Research. 24(16). 3829–3837. 78 indexed citations
6.
7.
Glaspy, John A., René González, Takami Sato, et al.. (2013). High-dose Vincristine Sulfate Liposome Injection (Marqibo) Is Not Associated With Clinically Meaningful Hematologic Toxicity. Clinical Lymphoma Myeloma & Leukemia. 14(3). 197–202. 19 indexed citations
8.
Rauh, Michael J., Fazlur Rahman, David Good, et al.. (2011). Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation, lacking cutaneous involvement: Case series and literature review. Leukemia Research. 36(1). 81–86. 66 indexed citations
9.
Hoch, Ute, Jennifer Lynch, Yuji Sato, et al.. (2008). Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Cancer Chemotherapy and Pharmacology. 64(1). 53–65. 52 indexed citations
10.
Reddy, Mamatha, et al.. (2007). SNS-032 has potent antitumor activity in vivo against human leukemia and multiple myeloma xenografts. Molecular Cancer Therapeutics. 6. 2 indexed citations
11.
Jones, Jeffrey J., et al.. (2007). SNS-595 potentiates the in vivo antitumor activity of carboplatin, cisplatin, and gemcitabine in solid tumor xenografts.. Molecular Cancer Therapeutics. 6. 3 indexed citations
12.
McEntee, Michael F., et al.. (2003). Enhanced bioavailability of oral docetaxel by co‐administration of cyclosporin A in dogs and rats. Veterinary and Comparative Oncology. 1(2). 105–112. 30 indexed citations
13.
Wosikowski, Katja, Jeffrey A. Silverman, Philippe C. Bishop, John Mendelsohn, & Susan E. Bates. (2000). Reduced growth rate accompanied by aberrant epidermal growth factor signaling in drug resistant human breast cancer cells. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1497(2). 215–226. 22 indexed citations
14.
Benet, Leslie Z., Takashi Izumi, Yuanchao Zhang, Jeffrey A. Silverman, & Vincent J. Wacher. (1999). Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. Journal of Controlled Release. 62(1-2). 25–31. 219 indexed citations
15.
Dintaman, Jay & Jeffrey A. Silverman. (1999). Inhibition of P-Glycoprotein by D-α-Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS). Pharmaceutical Research. 16(10). 1550–1556. 367 indexed citations
16.
Dintaman, Jay, et al.. (1998). Saquinavir, an HIV Protease Inhibitor, Is Transported by P-Glycoprotein. Journal of Pharmacology and Experimental Therapeutics. 286(3). 1439–1445. 151 indexed citations
17.
Schrenk, Dieter, et al.. (1994). Metabolic activation of 2-acetylaminofluorene is required for induction of multidrug resistance gene expression in rat liver cells. Carcinogenesis. 15(11). 2541–2546. 39 indexed citations
18.
Thorgeirsson, Snorri S., Timothy W. Gant, & Jeffrey A. Silverman. (1994). Transcriptional regulation of multidrug resistance gene expression. Cancer treatment and research. 73. 57–68. 7 indexed citations
19.
Brown, Paul C., Snorri S. Thorgeirsson, & Jeffrey A. Silverman. (1993). Cloning and regulation of the ratmdr2gene. Nucleic Acids Research. 21(16). 3885–3891. 72 indexed citations
20.
Gant, Timothy W., Jeffrey A. Silverman, & Snorri S. Thorgeirsson. (1992). Regulation of P-glycoprotein gene expression in hepatocyte cultures and liver cell lines by a trans-acting transcriptional repressor. Nucleic Acids Research. 20(11). 2841–2846. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Micheline Piquette‐Miller Breakdown of academic impact, for papers by Mikihisa Takano Breakdown of academic impact, for papers by Teruo Murakami Breakdown of academic impact, for papers by Jae‐Yong Chung Breakdown of academic impact, for papers by Johan W. Smit Breakdown of academic impact, for papers by Alan V. Boddy Breakdown of academic impact, for papers by Katsuhiko Okumura Breakdown of academic impact, for papers by Ashim K. Mitra Breakdown of academic impact, for papers by Masato Yasuhara Breakdown of academic impact, for papers by Sharon Marsh
Rankless by CCL
2026